Effect of GLP-1 on microvascular function in patients with type 2 diabetes

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2012-005013-38-DK

Enrollment

Registered

2013-02-04

Start date

2013-02-21

Completion date

Unknown

Last updated

2016-08-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Microvessel angina is a result of myocardial ischemia from insufficient myocardial perfusion secondary to microvessel dysfunction. Diseased arteries may appear angiographically normal but are dysfunctioning and blood flow is not sufficient increased. In the absence of stenosis of major coronary arteries, coronary flow reserve (CFR) reflects coronary microcirculation. CFR is reduced in patients diabetes and is a strong predictor of poor prognosis. MedDRA version: 14.1 Level: LLT Classification

Interventions

Trade Name: Victoza Product Name: liraglutid Pharmaceutical Form: Concentrate and solvent for solution for injection/infusion INN or Proposed INN: LIRAGLUTIDE CAS Number: 204656-20-2 Concentration uni

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Age: 40-75 years Type 2 diabetes with clinical indication of liraglutide treatment (not acceptable glycemic regulation on oral antidiabetic medication) BMI>25 kg/m2 HbA1c=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Insulin treatment HbA1c>9 %. Documented significant stenosis of the left anterior descending artery (LAD) at coronary angiography or CT-angiography. Pregnancy, physical or mental disability, active cancer, severe co-morbidity with limited life-expectancy, significant renal or hepatic co-morbidity, chronic alcohol abuse or heart failure with a left ventricular ejection fraction </= 45%, atrial fibrillation, chronic or previous acute pancreatitis, inflammatory bowel disease

Design outcomes

Primary

Measure	Time frame
Main Objective: The aim of this study is to explore the short term effects of GLP-1 treatment on coronary microcirculations estimated by coronary flow reserve (CFR) in patients with type 2 diabetes as a pilot study for a long term study;Secondary Objective: Not applicable;Primary end point(s): Coronary flow reserve (CFR). ;Timepoint(s) of evaluation of this end point: baseline, after 5 weeks and after 10 weeks of treatment	—

Measure

Time frame

Main Objective: The aim of this study is to explore the short term effects of GLP-1 treatment on coronary microcirculations estimated by coronary flow reserve (CFR) in patients with type 2 diabetes as a pilot study for a long term study;Secondary Objective: Not applicable;Primary end point(s): Coronary flow reserve (CFR). ;Timepoint(s) of evaluation of this end point: baseline, after 5 weeks and after 10 weeks of treatment

—

Secondary

Measure	Time frame
Secondary end point(s): Endothelial function. ;Timepoint(s) of evaluation of this end point: baseline, after 5 weeks and after 10 weeks of treatment	—

Countries

Denmark

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026